The role of comorbidity in the development of Long-COVID
ARTICLE PDF (Українська)


neuropsychological study
chronic brain ischemia

How to Cite

Chernii, T., Chernii, V. I., & Fokina, D. A. (2022). The role of comorbidity in the development of Long-COVID. Clinical and Preventive Medicine, (4), 30-36.


Introduction. Elimination of intracellular energy deficit and "smoldering" systemic inflammation, as well as elimination of water-electrolyte and metabolic disorders can be singled out as the main directions of therapy for the long-term consequences of Long COVID.

The aim: to study and analyze the results of treatment with a pathogenetically justified combination of drugs Xavron, Tivorel and Xylat in patients with asthenic manifestations in the framework of Long-COVID.

Materials and methods. During 2021, a clinical and neurological examination of 50 patients aged 47 to 76 years with a diagnosis of chronic cerebral ischemia (CMI) and an asthenic syndrome that persisted for more than 3 months after a laboratory-confirmed SARS-CoV-2 infection was carried out. The diagnosis was confirmed by the results of a clinical-neurological and neuropsychological examination using scales for the assessment of cognitive function (MMSE), emotional status (DASS-21), fatigue (FAS) and the neurological deficit assessment scale (MOND) developed by us. 20 patients additionally received a 10-day course of infusions of a combination of Xavron drugs in a dose of 30 mg No. 10, Tivorel 100.0 No. 5, and Xylate 200.0 No. 5 every other day, respectively. Thus, 50 patients were divided into two groups: the first - 20 people and the second - 30 people.

Results. Correlation analysis revealed a strong positive correlation between the CIRS-G comorbidity score and the MOND score. A positive correlation coefficient between comorbidity and asthenic syndrome, assessed on the FAS scale, was also expressed - 0.699 (p=<0.001).

A somewhat weaker negative relationship was found between anxiety and the number of points on the CIRS-G scale – -0.474 (p=0.035). At the same time, the assessment of other parameters on the DASS-21 scale, such as depression and stress, did not show a reliably significant correlation effect. Also, the severity of cognitive deficits in this group did not depend on the number of comorbid diseases. There was also a positive correlation coefficient between comorbidity and asthenic syndrome as assessed by FAS - 0.699 (p=<0.001). A weaker negative correlation was seen between anxiety and CIRS-G - -0.474 (p=0.035). However, other DASS-21 scores, such as depression and stress, did not show a significant correlation effect. Also, the severity of cognitive deficits in this group did not depend on the number of comorbidities. All patients who received treatment with a combination of Xavron, Tivorel and Xylat noted an improvement in general well-being and a decrease in the severity of neurological symptoms. Changes in the severity of neurological deficit in 30 patients with Long-COVID (MOND) of the second group after the completion of the treatment course were significantly lower than in the first research group (P<0.05).

Conclusions. The combination of Xavron, Tivorel and Xylat is pathogenetically primed and safe for the treatment of patients with long-covid. the use of this drug combination leads to reduction of asthenic syndrome, which, in turn, positively influences the reduction of cognitive manifestations of long-covid in the form of "brain fog".
ARTICLE PDF (Українська)


Gromova, O.A., Torshin, I.Y.u, Semenov, V.A., Putilina, M.V., Chuchalin, A.G. (2020). Direct and indirectneurologicalmanifestationsof COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry, 120(11), 11–21.

Vink, M,Vink-Niese, A. (2020). Could Cognitive Behavioural Therapy Bean Effective Treatment for Long COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome. Healthcare (Basel), 8(4), 552. doi:10.3390/healthcare8040552.

Mahase, E. (2020). Long Covid could be four different syndromes, review suggests. BMJ, 371, m3981. doi:10.1136/bmj.m3981.

Sacchi, M.C., Tamiazzo, S., Stobbione, P., Agatea, L., DeGaspari, P, Stecca, A., Lauritano, E.C., Roveta, A., Tozzoli, R., Guaschino, R., Bonometti, R. (2021). SARS-CoV-2 infectionas a trigger of autoimmune response. Clin Transl Sci.,14(3), 898-907. doi: 10.1111/cts.12953.

WHO: A clinical case definition of post COVID-19 condition by a Delphiconsensus (2021). 6 October 2021. doi: 10.1016 / S1473-3099(21)00703-9.

Halpin, S.J., McIvor, C., Whyatt , G., et al. (2021). Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J MedVirol., 93(2), 1013-1022. doi:10.1002/jmv.26368.

NICE guideline [NG188] (2021). COVID-19 rapidguideline: managing the long-term effects of COVID-19. Published: 18 December 2020. Lastupdated: 11 November 2021.

Rezolyutsiya telemostu «Medykamentozna reabilitatsiya patsiyentiv z Long COVID». 2 veresnya 2021 roku m. Kyyiv [Resolution of the telebridge "Medical rehabilitation of patients with Long COVID"] (2021). September 2, 2021, Kyiv, Ukraine. (In Ukrainian)

Cherniy, T.V., Fokina, D.O., Cherniy, V.I. Kompleksne likuvannya khvorykh z khronichnoyu ishemiyeyu mozku. Tsilespryamovana korektsiya kohnityvnykh porushenʹ ta vidnovlennya rukhovykh funktsiy pislya perenesenoho mozkovoho insulʹtu [Black Comprehensive treatment of patients with chronic brain ischemia. Targeted correction of cognitive impairments and restoration of motor functions after a stroke]. Clinical and preventive medicine, 4, 14, 33-43. doi: Ukrainian).

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.